Literature DB >> 23242946

Proteolytic cleavage of elafin by 20S proteasome may contribute to inflammation in acute lung injury.

Aoife Kerrin1, Sinéad Weldon, Allen Hung-Kang Chung, Thelma Craig, A John Simpson, Cecilia M O'Kane, Danny Francis McAuley, Clifford C Taggart.   

Abstract

RATIONALE: We hypothesise that elafin levels in acute lung injury (ALI) decrease over time due, in part, to proteolytic degradation as observed in other lung diseases.
OBJECTIVES: The aim of this study was to characterise temporal changes in elafin concentration in patients with ALI and to evaluate whether a decrease in elafin levels is due to elevated protease activity.
METHODS: Bronchoalveolar lavage fluid (BALF) was obtained from patients with ALI within 48 h of onset of ALI (day 0), at day 3 and at day 7. Elafin levels were quantified by ELISA. Elafin susceptibility to proteolytic cleavage by ALI BALF was assessed by Western blot and by high-performance liquid chromatography-mass spectrometry.
MEASUREMENTS AND MAIN RESULTS: Elafin levels were found to be significantly increased at the onset of ALI compared with healthy volunteers and fell significantly by day 7 compared with day 0. In contrast, levels of secretory leukocyte protease inhibitor did not decrease over time. This decrease in elafin was due to cleavage by the 20S proteasome which was significantly increased in ALI BALF. Incubation of ALI BALF with the proteasome inhibitor epoxomicin confirmed that 20S proteasome protease activity was responsible for proteolytic cleavage of elafin, resulting in diminished anti-elastase activity. In addition, free neutrophil elastase activity significantly increased in ALI BALF from day 0 to day 7.
CONCLUSIONS: Elafin concentrations fall within the pulmonary compartment over the course of ALI as a result of proteolytic degradation. This loss of elafin may predispose people, in part, to excessive inflammation in ALI.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23242946     DOI: 10.1136/thoraxjnl-2012-202536

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  6 in total

1.  The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.

Authors:  G R Tundo; D Sbardella; A M Santoro; A Coletta; F Oddone; G Grasso; D Milardi; P M Lacal; S Marini; R Purrello; G Graziani; M Coletta
Journal:  Pharmacol Ther       Date:  2020-05-19       Impact factor: 12.310

2.  A functional variant of elafin with improved anti-inflammatory activity for pulmonary inflammation.

Authors:  Donna M Small; Marie-Louise Zani; Derek J Quinn; Sandrine Dallet-Choisy; Arlene M A Glasgow; Cecilia O'Kane; Danny F McAuley; Paul McNally; Sinéad Weldon; Thierry Moreau; Clifford C Taggart
Journal:  Mol Ther       Date:  2014-09-05       Impact factor: 11.454

Review 3.  Proteases, Mucus, and Mucosal Immunity in Chronic Lung Disease.

Authors:  Michael C McKelvey; Ryan Brown; Sinéad Ryan; Marcus A Mall; Sinéad Weldon; Clifford C Taggart
Journal:  Int J Mol Sci       Date:  2021-05-09       Impact factor: 5.923

4.  The serine protease inhibitor elafin maintains normal growth control by opposing the mitogenic effects of neutrophil elastase.

Authors:  J A Caruso; S Akli; L Pageon; K K Hunt; K Keyomarsi
Journal:  Oncogene       Date:  2014-09-08       Impact factor: 9.867

5.  Clinical significance of PI3 and HLA-DOB as potential prognostic predicators for ovarian cancer.

Authors:  Yanrong Li; Haixia Li; Baojun Yang; Jing Wei; Cheng Zhen; Limin Feng
Journal:  Transl Cancer Res       Date:  2020-02       Impact factor: 1.241

6.  Emerging pharmacological therapies for ARDS: COVID-19 and beyond.

Authors:  Shahd Horie; Bairbre McNicholas; Emanuele Rezoagli; Tài Pham; Ger Curley; Danny McAuley; Cecilia O'Kane; Alistair Nichol; Claudia Dos Santos; Patricia R M Rocco; Giacomo Bellani; John G Laffey
Journal:  Intensive Care Med       Date:  2020-07-11       Impact factor: 41.787

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.